Seeking Alpha
 

Oncothyreon Inc . (ONTY)

- NASDAQ
Show Summaries  |  Hide Summaries
  • Sep. 3, 2013, 3:57 PM
  • Aug. 6, 2013, 4:08 PM
    | Comment!
  • Aug. 6, 2013, 12:10 AM
  • Aug. 5, 2013, 5:35 PM
  • May 30, 2013, 9:00 AM
    Colfax Capital is distinctly unimpressed by Oncothyreons (ONTY) development deal with Array. "What a lousy company," Colax tweets. "Now inlicensing other compounds from ARRY while they inlicensed a Bcl last year that is collecting dust." The market is yet to pass its judgement.
    | 1 Comment
  • May 30, 2013, 8:40 AM
    Oncothyreon (ONTY) agrees to pay Array BioPharma (ARRY) $10M as part of a deal to collaborate on developing the latter's ARRY-380 molecule for treating breast and other cancers. Oncothyreon is raising the $10M by selling 5M shares and warrants for another 5M shares to BVF Partners.
    | Comment!
  • May 17, 2013, 3:56 PM
    Oncothyreon (ONTY +0.9%) gets a boost from Wedbush today, as the firm upgrades he stock to Outperform and raises the price target from $2 to $5. Wedbush says that its partner Merck KgA may be successful in negotiating a path to approval for Stimuvax with the existing and anticipated new data from ongoing clinical trials. Merck expects to provide an update on their discussion with regulators in 2013.
    | 1 Comment
  • May 16, 2013, 12:55 PM
    Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY.
    | 3 Comments
  • May 16, 2013, 12:51 PM
    Midday top 10 gainers: EGLE +46%. NBG +24%. SBSA +23%. DQ +22%. GNK +19%. AEGR +19%. GLBS +17%. SINO +17%. PRGN +16%. LWAY +16%.
    Midday top 10 losers: NCT -54%. SNFCA -22%. ONTY -21%. INFI -19%. CNIT -15%. CYCC -14%. PTSX -14%. AMD -13%. BDCO -11%. TRIT -11%.
    | 2 Comments
  • May 9, 2013, 5:54 PM
    After-hours top gainers, as of 5:30 p.m.: UBNT +10%. UNIS +10%. MCP +7%. WIFI +7%. DAR +6%.
    After-hours top losers: ONTY -10%. AL -8%. AIRM -7%. SNTS -6%. TSEM -6%.
    | Comment!
  • Mar. 15, 2013, 3:08 PM
    Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely shrugging off Cantor Fitzgerald's slashing of its price target to $4.00 from $11.00. The cut relates to ONTY's loss of Stimuvax. Cantor says that despite partner Merck's (MRK) assertion that treatment effects were observed in sub-populations, its financial model assumes that commercialization does not occur and no value is included in its valuation.
    | Comment!
  • Mar. 14, 2013, 8:17 AM
    Oncothyreon (ONTY): Q4 EPS of -$0.12 beats by $0.02. (PR)
    | Comment!
  • Jan. 2, 2013, 9:10 AM
    Premarket gainers: ZIP +47.94%. POL +18.71%. SGYP +16.92%. MCP +9%. JRCC +8.41%. PAL +7.69%. KWK +7.69%. ZGNX +7.52%. PPHM +6.82%. ONTY +6.77%.
    Losers: ABT -50%.
    | 6 Comments
  • Dec. 19, 2012, 12:45 PM
    Midday top 10 gainers: AMPL +119%. DYNT +64%. EDAP +25%. ALTE +24%. STP +16%. PTNR +13%. LDK +12%. GBR +19%. CSUN +12%. ELTK +12%.
    Midday top 10 Losers: ONTY -54%. CMGE -21%. PLXT -18%. NICK -15%. DLB -12%. PNTR -11%. PSDV -10%. EGLE -10%. CCUR -10%. PTEK -10%.
    | Comment!
  • Dec. 19, 2012, 9:10 AM
    Premarket gainers: PTNR +11%. GM +9%. KCG +8%. RMCF +6%. NBG +6%. VRNG +6%. MLNX +5%
    Losers: ONTY -61%. PLXT -18%. NAV -6%. CYS -6%.
    | 3 Comments
  • Dec. 19, 2012, 8:39 AM
    Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR)
    | Comment!
Visit Seeking Alpha's
ONTY vs. ETF Alternatives
Company Description
Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.
Sector: Healthcare
Industry: Biotechnology
Country: United States